Huang Rong, Zhang Wenyu, Hu Yueqi, Xu Junjie, Dong Zhihui, Liu Jikai, Zhou Li
The Modernization Engineering Technology Research Center of Ethnic Minority Medicine of Hubei Province, School of Pharmaceutical Sciences, South-Central Minzu University, Wuhan 430074, PR China; National Demonstration Center for Experimental Ethnopharmacology Education, South-Central Minzu University, Wuhan 430074, PR China.
The Modernization Engineering Technology Research Center of Ethnic Minority Medicine of Hubei Province, School of Pharmaceutical Sciences, South-Central Minzu University, Wuhan 430074, PR China.
Int J Biol Macromol. 2025 Jun;314:144264. doi: 10.1016/j.ijbiomac.2025.144264. Epub 2025 May 18.
Atopic dermatitis (AD), a prevalent inflammatory skin condition, significantly impacts patients' quality of life due to the multifaceted etiology and the lack of targeted therapeutic options. As the "Chinese herbal antibiotic", Houttuynia cordata is renowned for its diverse pharmacological attributes. This study aims to investigate the therapeutic potential of Houttuynia cordata polysaccharides (HCP) in treating AD and to elucidate the mechanisms involved. HCP alleviated AD in MC903-induced mice by reducing epidermal thickness, skin lesions, mast cell infiltration, inflammatory cytokines, and restoring barrier proteins. It also suppressed inflammatory cytokines/chemokines via the mitogen-activated protein kinase (MAPK) pathway in lipopolysaccharide (LPS)-stimulated RAW264.7 cells and tumor necrosis factor-alpha (TNF-α)/ interferon-γ(IFN-γ)-induced human keratinocytes cells (HaCaT). Moreover, HCP modulated inflammation-related metabolic pathways, especially restored lipid metabolic homeostasis through upregulating phosphatidylcholine (PC) and downregulating triglyceride (TG), lysophosphatidylcholine (LPC), potentially alleviating AD-like lesions and restoring barrier function. Our findings underscore the promising potential of HCP as a topical therapeutic candidate for AD treatment, offering a new direction for the development of targeted AD therapies.
特应性皮炎（AD）是一种常见的炎症性皮肤病，由于其病因多方面且缺乏针对性治疗选择，严重影响患者的生活质量。作为“中草药抗生素”，鱼腥草以其多样的药理特性而闻名。本研究旨在探讨鱼腥草多糖（HCP）治疗AD的潜力，并阐明其相关机制。HCP通过减少表皮厚度、皮肤损伤、肥大细胞浸润、炎性细胞因子以及恢复屏障蛋白，减轻了MC903诱导的小鼠的AD症状。它还通过丝裂原活化蛋白激酶（MAPK）途径抑制脂多糖（LPS）刺激的RAW264.7细胞以及肿瘤坏死因子-α（TNF-α）/干扰素-γ（IFN-γ）诱导的人角质形成细胞（HaCaT）中的炎性细胞因子/趋化因子。此外，HCP调节炎症相关的代谢途径，特别是通过上调磷脂酰胆碱（PC）和下调甘油三酯（TG）、溶血磷脂酰胆碱（LPC）来恢复脂质代谢稳态，可能减轻AD样病变并恢复屏障功能。我们的研究结果强调了HCP作为AD治疗局部治疗候选药物的潜在前景，为靶向AD治疗的发展提供了新方向。
